Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
Recent Advances in Gastrointestinal Cancers: From Microbiota Modulation to New...
share announcement

Recent Advances in Gastrointestinal Cancers: From Microbiota Modulation to New Therapeutic Approaches

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 597

Special Issue Editors

Dr. Serena Martinelli

E-Mail Website
Guest Editor
Department of Experimental and Clinical Medicine, University of Florence, 50139 Florence, Italy
Interests: oncology; metastasis; cell cultures; 3D models; cancer organoids; microbiota
Special Issues, Collections and Topics in MDPI journals
Dr. Elena Niccolai

E-Mail Website1 Website2
Guest Editor
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
Interests: microbiome; immunology; gastrointestinal cancers; nutrition; gut-brain axis; neurodegeneration; neuroinflammation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Malignant tumors that affect the gastrointestinal tract, known as gastrointestinal (GI) cancers, are widespread. Globally, GI cancers are estimated to be responsible for one in four cancer cases and one in three deaths. This Special Issue aims to elucidate potential areas of progress in the field of GI cancers, including the modulation of the microbiota and novel therapeutic approaches.

Research areas may include (but are not limited to) the following:

  • Modulation of the microbiota: role of the gut microbiome in influencing GI cancer development and response to treatment; manipulation of the microbiota through interventions such as probiotics, prebiotics, and fecal microbiota transplantation; and methods of modulating the microbiome to enhance response to immunotherapies, such as checkpoint inhibitors.
  • Immunotherapy: efficacy of checkpoint inhibitors, such as pembrolizumab and nivolumab, in various GI malignancies and the exploration of CAR-T potential in GI cancers.
  • Precision medicine: advances in molecular profiling and genomics, leading to the identification of specific biomarkers associated with GI cancers, and the development of liquid biopsy techniques for monitoring GI cancers.
  • Targeted therapies: identify additional targeted therapies for specific subtypes of GI cancers in addition to HER2 therapies.
  • Artificial intelligence in diagnostics: evaluation of machine learning algorithms to analyze medical images and to predict the prognosis and disease outcomes of GI cancers.

Dr. Serena Martinelli
Dr. Elena Niccolai
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastrointestinal cancers
  • microbiota
  • anticancer therapy
  • immunotherapy
  • precision medicine

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 2030 KiB  
Article
The Interplay among Wnt/β-catenin Family Members in Colorectal Adenomas and Surrounding Tissues
by Domenica Lucia D’Antonio, Fabiana Fantini, Carmelo Moscatello, Alessio Ferrone, Stefano Scaringi, Rosa Valanzano, Ferdinando Ficari, Konstantinos Efthymakis, Matteo Neri, Gitana Maria Aceto and Maria Cristina Curia
Biomedicines 2024, 12(8), 1730; https://doi.org/10.3390/biomedicines12081730 - 2 Aug 2024
Viewed by 356
Abstract
Background: The colorectal adenoma undergoes neoplastic progression via the normal epithelium–adenoma–adenocarcinoma sequence as reported in the Vogelgram. The hazard of developing a tumor is deeply associated with the number and size of adenomas and their subtype. Adenomatous polyps are histologically categorized as follows: [...] Read more.
Background: The colorectal adenoma undergoes neoplastic progression via the normal epithelium–adenoma–adenocarcinoma sequence as reported in the Vogelgram. The hazard of developing a tumor is deeply associated with the number and size of adenomas and their subtype. Adenomatous polyps are histologically categorized as follows: approximately 80–90% are tubular, 5–15% are villous, and 5–10% are tubular/villous. Given the higher risk of a malignant transformation observed in tubular/villous adenomas, patients diagnosed with adenomatous polyposis are at an improved risk of developing CRC. The Wnt/β-catenin pathway plays a key role in the onset of colorectal adenoma; in particular, intestinal cells first acquire loss-of-function mutations in the APC gene that induce the formation of adenomas. Methods: Wnt/β-catenin pathway APC, Wnt3a, Wnt5a, LEF1, and BCL9 genes and protein expression analyses were conducted by qRT-PCR and western blot in 68 colonic samples (polyps and adjacent mucosa) from 41 patients, of which 17 were affected by FAP. Ten normal colonic mucosal samples were collected from 10 healthy donors. Results: In this study, both the APC gene and protein were less expressed in the colon tumor compared to the adjacent colonic mucosa. Conversely, the activated β-catenin was more expressed in polyps than in the adjacent mucosa. All results confirmed the literature data on carcinomas. A statistically significant correlation between Wnt3a and BCL9 both in polyps and in the adjacent mucosa underlines that the canonical Wnt pathway is activated in early colon carcinogenesis and that the adjacent mucosa is already altered. Conclusion: This is the first study analyzing the difference in expression of the Wnt/β-catenin pathway in human colorectal adenomas. Understanding the progression from adenomas to colorectal carcinomas is essential for the development of new therapeutic strategies and improving clinical outcomes with the use of APC and β-catenin as biomarkers. Full article
(This article belongs to the Special Issue Recent Advances in Gastrointestinal Cancers: From Microbiota Modulation to New Therapeutic Approaches)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop